427 related articles for article (PubMed ID: 24443409)
21. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
22. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment.
Buijs JT; Que I; Löwik CW; Papapoulos SE; van der Pluijm G
Bone; 2009 Feb; 44(2):380-6. PubMed ID: 19041433
[TBL] [Abstract][Full Text] [Related]
24. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
[TBL] [Abstract][Full Text] [Related]
25. RANKL synthesized by both stromal cells and cancer cells plays a crucial role in osteoclastic bone resorption induced by oral cancer.
Sato K; Lee JW; Sakamoto K; Iimura T; Kayamori K; Yasuda H; Shindoh M; Ito M; Omura K; Yamaguchi A
Am J Pathol; 2013 May; 182(5):1890-9. PubMed ID: 23499553
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone.
Lau CP; Huang L; Wong KC; Kumta SM
Connect Tissue Res; 2013; 54(6):439-49. PubMed ID: 24060052
[TBL] [Abstract][Full Text] [Related]
27. Resolvin E1 Promotes Bone Preservation Under Inflammatory Conditions.
El Kholy K; Freire M; Chen T; Van Dyke TE
Front Immunol; 2018; 9():1300. PubMed ID: 29946319
[TBL] [Abstract][Full Text] [Related]
28. RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases.
Miller RE; Jones JC; Tometsko M; Blake ML; Dougall WC
J Thorac Oncol; 2014 Mar; 9(3):345-54. PubMed ID: 24496001
[TBL] [Abstract][Full Text] [Related]
29. Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades.
Song F; Wei C; Zhou L; Qin A; Yang M; Tickner J; Huang Y; Zhao J; Xu J
J Cell Physiol; 2018 Feb; 233(2):1723-1735. PubMed ID: 28681916
[TBL] [Abstract][Full Text] [Related]
30. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH
Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111
[TBL] [Abstract][Full Text] [Related]
31. The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis.
Koreny T; Tunyogi-Csapó M; Gál I; Vermes C; Jacobs JJ; Glant TT
Arthritis Rheum; 2006 Oct; 54(10):3221-32. PubMed ID: 17009257
[TBL] [Abstract][Full Text] [Related]
32. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
33. MCP-1 expressed by osteoclasts stimulates osteoclastogenesis in an autocrine/paracrine manner.
Miyamoto K; Ninomiya K; Sonoda KH; Miyauchi Y; Hoshi H; Iwasaki R; Miyamoto H; Yoshida S; Sato Y; Morioka H; Chiba K; Egashira K; Suda T; Toyama Y; Miyamoto T
Biochem Biophys Res Commun; 2009 Jun; 383(3):373-7. PubMed ID: 19364494
[TBL] [Abstract][Full Text] [Related]
34. Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies.
Higgs JT; Jarboe JS; Lee JH; Chanda D; Lee CM; Deivanayagam C; Ponnazhagan S
Mol Cancer Res; 2015 May; 13(5):819-27. PubMed ID: 25636966
[TBL] [Abstract][Full Text] [Related]
35. Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.
Yamakawa Y; Tazawa H; Hasei J; Osaki S; Omori T; Sugiu K; Komatsubara T; Uotani K; Fujiwara T; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Sci; 2017 Sep; 108(9):1870-1880. PubMed ID: 28685948
[TBL] [Abstract][Full Text] [Related]
36. Paclitaxel inhibits osteoclast formation and bone resorption via influencing mitotic cell cycle arrest and RANKL-induced activation of NF-κB and ERK.
Ang ES; Pavlos NJ; Chim SM; Feng HT; Scaife RM; Steer JH; Zheng MH; Xu J
J Cell Biochem; 2012 Mar; 113(3):946-55. PubMed ID: 22034016
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of osteoclast differentiation and bone resorption by sauchinone.
Han KY; Yang D; Chang EJ; Lee Y; Huang H; Sung SH; Lee ZH; Kim YC; Kim HH
Biochem Pharmacol; 2007 Sep; 74(6):911-23. PubMed ID: 17662251
[TBL] [Abstract][Full Text] [Related]
38. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
[TBL] [Abstract][Full Text] [Related]
39. Melatonin attenuates titanium particle-induced osteolysis via activation of Wnt/β-catenin signaling pathway.
Ping Z; Hu X; Wang L; Shi J; Tao Y; Wu X; Hou Z; Guo X; Zhang W; Yang H; Xu Y; Wang Z; Geng D
Acta Biomater; 2017 Mar; 51():513-525. PubMed ID: 28088671
[TBL] [Abstract][Full Text] [Related]
40. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
